TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Pulmonary hemorrhage rate
Endpoint domain: Adverse events/effects
Primary endpoint: Difference in temperature between decubitus pressure ulcer stages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Median Time Between Event Onset Time and Clinical Decision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined Endpoint of Death From Any Cause, Cardiovascular and Device-related Hospitalizations
Endpoint domain: Mortality/survival
Primary endpoint: Changes in pain scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analogue Scale of Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Patients That Undergo Successful SVG Procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Acute hematotoxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Acute infection rate
Endpoint domain: Adverse events/effects
Primary endpoint: changes in mitochondrial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: lipid accumulation in ectopic tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Vaginal vault infection
Endpoint domain: Adverse events/effects
Primary endpoint: Dehiscence of vaginal vault suture
Endpoint domain: Adverse events/effects
Primary endpoint: Pin sites condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Radiographs measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to complete successful pre-pubic delivery approach and mesh placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of complications associated with the pre-pubic delivery approach and mesh placement
Endpoint domain: Adverse events/effects
Primary endpoint: Physician-Procedure satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of patients achieving a response (CR+R)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of severe toxicity (grade III/IV)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Completing the Trial
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants Able to Complete Assessments
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Progression Rate of Emphysema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Minutes of Moderate to Vigorous Physical Activity (MVPA)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Freedom from documented AF/AT recurrences without new AADs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of PV Stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Visual image quality of LGE-CMR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantitative signal enhancement of LGE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Association of LGE and clinical cardiovascular outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incidence of hemidiaphragmatic paralysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Health related quality of life, EQ-5D
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Patients With Treatment Emergent Adverse Events (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of Treatment Emergent Adverse Events (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Measurement of Tumor Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Difficulties in Emotion Regulation Scale (DERS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Burden Assessment Scale (BAS)
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Three-year disease free survival
Endpoint domain: Mortality/survival
Primary endpoint: Success rate of cure of IH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Time of Retention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hamilton Depression Scale (HAMD-17)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: resistance profiling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prescription patterns
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of IAA-infection at ICU discharge
Endpoint domain: Adverse events/effects
Primary endpoint: Blood ropivacaine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in BCVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Duration of Hypoxemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Total number of TB patients registered and starting treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time to the first opioids request
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in gingival condition as measured by the Modified Lobene Gingival Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in gingival condition as measured by the Saxton van der Ouderaa bleeding index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in plaque levels as measured by the Quigley and Hein Plaque index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Events
Endpoint domain: Adverse events/effects
Primary endpoint: mean morning PEFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: free fatty acids (FFA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Amount of breast milk produced
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patient rated physical functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Area Under the Curve to Time Infinity (AUC to Time Infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve to 8h (AUC Last)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All stroke and systemic embolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Performance of serial PSP values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of Crohn's disease Activity score by 100 points or more
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cortical Oscillations - EEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Quality measures
Endpoint domain: Resource use
Primary endpoint: Change in gastrointestinal complaints
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants With Medication Related (Thromboembolic) Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Post-ICU dyspnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in Cortisol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in epinephrine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in norepinephrine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Neurocognitive functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Good biocompatibility of intraocular lens implants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Time the Patient Will Experience Apnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) Using the Cockcroft-Gault (CG) Equation at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change From Baseline in Actual Glomerular Filtration Rate (aGFR) at Weeks 2, 4, and 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Accuracy of SLNB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical outcomes after cardiac surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Percent Wall Volume (PWV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intracranial Pressure (ICP) >25mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Severe Anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants Who Experienced First Documented Relapse
Endpoint domain: Adverse events/effects
Primary endpoint: Adjusted Mean Percent Changes in Soluble CD40 Ligand (sCD40L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Factor VIII (FVIII) Inhibitor Development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean Total Number of Bleeding Episodes in Participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Need for mechanical ventilation (MV)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Kidney Stone Clearance Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Accuracy of CHIRON® RIBA® HCV 3.0
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Difference in gut microbiomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time to recurrence of Clostridium Difficile Infection (CDI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Degree of improvement of epiphora by Munk score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of improvement of lacrimal drainage by Dye disappearance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Slit lamp assessment of the state of the lower punctum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of having sleep apnea
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Number of Adverse Device Effects (ADE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Device Deficiencies (DD)
Endpoint domain: Adverse events/effects
Primary endpoint: First episode of acute rejection
Endpoint domain: Adverse events/effects
Primary endpoint: Measured Mechanical Axis of the Knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from baseline Oral Health Impact Profile (OHIP-14) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes from baseline Xerostomia Inventory score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes from baseline EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes from baseline Ocular Surface Disease Index (OSDI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Weight-for-age Z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of ACPA-expressing B cells expressing Ki-67
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants Achieving Clinical Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically relevant beta cell function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Rate of remission (CR, PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in calciphylaxis skin lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change From Baseline in Worst Itching Intensity NRS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease activity monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of optimum position of the double-lumen tube
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reduction in global symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: death after 5 years
Endpoint domain: Mortality/survival
Primary endpoint: Sensitivity of OraTest + Visual Exam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor response measured by RECIST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: T-cell responses to vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Compliance in treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ankle dorsiflexion angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration versus Time Curve (AUC[0 tlast])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC from Zero to Infinity (AUC[0 - inf])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of transfusion episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pain Sensitivity to Various Experimentally Induced Pain Stimuli (Upper Extremity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Sensitivity to Various Experimentally Induced Pain Stimuli (Lower Extremity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of aspirin and Plavix resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Acute PEC (post-ERCP-cholecystitis)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients with Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: MTDs of HM95573 and cobimetinib, or HM95573 and cetuximab
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical relationship quality
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Responder Rate After Active rTMS Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improve dyspnea score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change From Baseline in ADAS-Cog11 Total Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Treatment Satisfaction Questionnaire for Medication (TQSM)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Client Satisfaction Questionnaire (CSQ-8)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Levels of inflammatory biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Vitreous levels of Fractalkine, Cyr61, and VEGF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax (time to maximum plasma concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of Nursing Activity
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Post operative Morphine requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Program Feasibility and Efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage Difference Between VMS and MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CDI recurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Effectiveness of lobaplatin combined with docetaxel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Bithermal calorics asymmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Severity of hepatobiliary manifestations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Catheter Related Blood Stream Infections (CRBSI)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with drug-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Infusion Reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Graft Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of infants that develop bradycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of Symptomatic, Recurrent Venous Thromboembolism or VTE-Related Death
Endpoint domain: Mortality/survival
Primary endpoint: Absence of endoleak
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Participants Achieving Clinical Remission at Week 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Enhanced Clinical Response at Week 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of time on NIPPV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Micrograms of rigosertib per milliliter of plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Micrograms of rigosertib per milliliter of urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms of posttraumatic stress disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radlex Scale for Diagnostic Quality Ratings - 2D Images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radlex Scale for Diagnostic Quality Ratings - 3D Images High Resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radlex Scale for Diagnostic Quality Ratings - 3D Images FDK
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radlex Scale for Diagnostic Quality Ratings - 3D Images SND
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total range of movement of the injured finger
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of frequency and intensity of physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of positive mental health on 39 points of the Positive Mental Health Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline of the BMI of participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speech Intelligibility Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Device Performance Rating Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Device Satisfaction Rating Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Improvement in verbal and nonverbal communication
Endpoint domain: Life impact
Endpoint subdomain: Communication functioning
Primary endpoint: Bone Mineral Density of the Total Hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of Tolvaptan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve From Time Zero to the Last Observable Concentration at Time t (AUCt) of Tolvaptan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the AHI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Blood loss in postpartum period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Duration of penile erections with 60% rigidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy Assessment post implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adequate compression rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Face inversion effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain connectivity and activation in the dorsal and ventral visual stream
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes